222 related articles for article (PubMed ID: 10947491)
1. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.
Sculpher M; Palmer MK; Heyes A
Pharmacoeconomics; 2000 Apr; 17(4):361-70. PubMed ID: 10947491
[TBL] [Abstract][Full Text] [Related]
2. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
3. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens.
Ross P; Heron J; Cunningham D
Eur J Cancer; 1996; 32A Suppl 5():S13-7. PubMed ID: 8958037
[TBL] [Abstract][Full Text] [Related]
4. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?].
Carnaghi C; Zucali P; Garassino I
Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298
[TBL] [Abstract][Full Text] [Related]
5. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer.
Groener MG; van Ineveld BM; Byttebier G; van Hout BA; Rutten FF
Anticancer Drugs; 1999 Mar; 10(3):283-8. PubMed ID: 10327033
[TBL] [Abstract][Full Text] [Related]
6. [Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial].
Locher C; Auperin A; Boige V; Alzieu L; Pignon JP; Abbas M; Ducreux M
Gastroenterol Clin Biol; 2001; 25(8-9):749-54. PubMed ID: 11598535
[TBL] [Abstract][Full Text] [Related]
7. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
Maroun J; Asche C; Romeyer F; Mukherjee J; Cripps C; Oza A; Skillings J; Letarte J
Pharmacoeconomics; 2003; 21(14):1039-51. PubMed ID: 13129416
[TBL] [Abstract][Full Text] [Related]
8. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
Borget I; Aupérin A; Pignon JP; Abbas M; Bouché O; Mousseau M; Raoul JL; Bedenne L; Cassan P; Clavero-Fabri MC; Stremsdoerfer N; Nasca S; Queuniet AM; Ducreux M;
Oncology; 2006; 71(1-2):40-8. PubMed ID: 17344670
[TBL] [Abstract][Full Text] [Related]
10. Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics.
Norum J; Balteskard L; Edna TH; Laino R; Wählby L; Rønning G
J Chemother; 2002 Jun; 14(3):301-8. PubMed ID: 12120887
[TBL] [Abstract][Full Text] [Related]
11. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
Ducreux M; Bouche O; Pignon JP; Mousseau M; Raoul JL; Cassan P; Leduc B; Berger C; Dunant A; Fournet J; Bedenne L;
Oncology; 2006; 70(3):222-30. PubMed ID: 16816536
[TBL] [Abstract][Full Text] [Related]
12. Mature results from three large controlled studies with raltitrexed ('Tomudex').
Cunningham D
Br J Cancer; 1998; 77 Suppl 2(Suppl 2):15-21. PubMed ID: 9579851
[TBL] [Abstract][Full Text] [Related]
13. Raltitrexed-based chemotherapy for advanced colorectal cancer.
Liu Y; Wu W; Hong W; Sun X; Wu J; Huang Q
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):219-25. PubMed ID: 24388340
[TBL] [Abstract][Full Text] [Related]
14. Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
Tse VC; Ng WT; Lee V; Lee AW; Chua DT; Chau J; McGhee SM
BMC Cancer; 2011 Jul; 11():288. PubMed ID: 21740590
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Avallone A; Di Gennaro E; Bruzzese F; Laus G; Delrio P; Caraglia M; Pepe S; Comella P; Budillon A
Anticancer Drugs; 2007 Aug; 18(7):781-91. PubMed ID: 17581300
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for colorectal cancer.
Goyle S; Maraveyas A
Dig Surg; 2005; 22(6):401-14. PubMed ID: 16479107
[TBL] [Abstract][Full Text] [Related]
17. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
Ducreux M; Van Cutsem E; Van Laethem JL; Gress TM; Jeziorski K; Rougier P; Wagener T; Anak O; Baron B; Nordlinger B;
Eur J Cancer; 2005 Feb; 41(3):398-403. PubMed ID: 15691639
[TBL] [Abstract][Full Text] [Related]
18. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.
Cunningham D; Zalcberg JR; Rath U; Oliver I; van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G
Ann Oncol; 1996 Nov; 7(9):961-5. PubMed ID: 9006748
[No Abstract] [Full Text] [Related]
19. A patient preference study comparing raltitrexed ('Tomudex') and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes.
Young A; Topham C; Moore J; Turner J; Wardle J; Downes M; Evans V; Kay S
Eur J Cancer Care (Engl); 1999 Sep; 8(3):154-61. PubMed ID: 10763646
[TBL] [Abstract][Full Text] [Related]
20. Conjoint analysis of a new Chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced Colorectal Cancer.
Aristides M; Chen J; Schulz M; Williamson E; Clarke S; Grant K
Pharmacoeconomics; 2002; 20(11):775-84. PubMed ID: 12201796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
